Acquiring Akorn would add around $ 1 billion in annual sales to Fresenius» drugmaking division, giving it a significantly larger presence in eyecare and other areas widely perceived as somewhat insulated
from generic drug pricing pressure.
Not exact matches
Prices for roughly 300
generic drugs at least doubled
from 2010 to 2015.
A 2012 report by the Kaiser Family Foundation calls the PBM assertions of Medicare savings «overstated» and says the reduced cost probably stemmed
from incorrectly high predictions of
prices and
from brand
drugs going
generic.
Another bright spot could be the slowing in the decline of U.S.
generic drug prices, according to report
from Credit Suisse, citing data
from health information company IQVIA.
Generic drug giant Mylan is cutting its financial outlook as it continues to face pressure from falling generic drug prices (a fate that similarly struck rival Teva Pharmaceut
Generic drug giant Mylan is cutting its financial outlook as it continues to face pressure
from falling
generic drug prices (a fate that similarly struck rival Teva Pharmaceut
generic drug prices (a fate that similarly struck rival Teva Pharmaceuticals).
Given its areas of specialization, Gilead wouldn't benefit as much
from consolidation as, say, a
generic -
drug company would, but it still faces
pricing pressure: To appease Medicaid and other insurers, Gilead is already steeply discounting its hep - C
drugs, which can cost more than $ 80,000 for a 12 - week course.
These risks and uncertainties include: Gilead's ability to achieve its anticipated full year 2018 financial results; Gilead's ability to sustain growth in revenues for its antiviral and other programs; the risk that private and public payers may be reluctant to provide, or continue to provide, coverage or reimbursement for new products, including Vosevi, Yescarta, Epclusa, Harvoni, Genvoya, Odefsey, Descovy, Biktarvy and Vemlidy ®; austerity measures in European countries that may increase the amount of discount required on Gilead's products; an increase in discounts, chargebacks and rebates due to ongoing contracts and future negotiations with commercial and government payers; a larger than anticipated shift in payer mix to more highly discounted payer segments and geographic regions and decreases in treatment duration; availability of funding for state AIDS
Drug Assistance Programs (ADAPs); continued fluctuations in ADAP purchases driven by federal and state grant cycles which may not mirror patient demand and may cause fluctuations in Gilead's earnings; market share and price erosion caused by the introduction of generic versions of Viread and Truvada, an uncertain global macroeconomic environment; and potential amendments to the Affordable Care Act or other government action that could have the effect of lowering prices or reducing the number of insured patients; the possibility of unfavorable results from clinical trials involving investigational compounds; Gilead's ability to initiate clinical trials in its currently anticipated timeframes; the levels of inventory held by wholesalers and retailers which may cause fluctuations in Gilead's earnings; Kite's ability to develop and commercialize cell therapies utilizing the zinc finger nuclease technology platform and realize the benefits of the Sangamo partnership; Gilead's ability to submit new drug applications for new product candidates in the timelines currently anticipated; Gilead's ability to receive regulatory approvals in a timely manner or at all, for new and current products, including Biktarvy; Gilead's ability to successfully commercialize its products, including Biktarvy; the risk that physicians and patients may not see advantages of these products over other therapies and may therefore be reluctant to prescribe the products; Gilead's ability to successfully develop its hematology / oncology and inflammation / respiratory programs; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (the S
Drug Assistance Programs (ADAPs); continued fluctuations in ADAP purchases driven by federal and state grant cycles which may not mirror patient demand and may cause fluctuations in Gilead's earnings; market share and
price erosion caused by the introduction of
generic versions of Viread and Truvada, an uncertain global macroeconomic environment; and potential amendments to the Affordable Care Act or other government action that could have the effect of lowering
prices or reducing the number of insured patients; the possibility of unfavorable results
from clinical trials involving investigational compounds; Gilead's ability to initiate clinical trials in its currently anticipated timeframes; the levels of inventory held by wholesalers and retailers which may cause fluctuations in Gilead's earnings; Kite's ability to develop and commercialize cell therapies utilizing the zinc finger nuclease technology platform and realize the benefits of the Sangamo partnership; Gilead's ability to submit new
drug applications for new product candidates in the timelines currently anticipated; Gilead's ability to receive regulatory approvals in a timely manner or at all, for new and current products, including Biktarvy; Gilead's ability to successfully commercialize its products, including Biktarvy; the risk that physicians and patients may not see advantages of these products over other therapies and may therefore be reluctant to prescribe the products; Gilead's ability to successfully develop its hematology / oncology and inflammation / respiratory programs; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (the S
drug applications for new product candidates in the timelines currently anticipated; Gilead's ability to receive regulatory approvals in a timely manner or at all, for new and current products, including Biktarvy; Gilead's ability to successfully commercialize its products, including Biktarvy; the risk that physicians and patients may not see advantages of these products over other therapies and may therefore be reluctant to prescribe the products; Gilead's ability to successfully develop its hematology / oncology and inflammation / respiratory programs; safety and efficacy data
from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock
price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified
from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (the SEC).
WASHINGTON (AP)-- Some low - cost
generic drugs that have helped restrain health care costs for decades are seeing unexpected
price spikes of up to 8,000 percent, prompting a backlash
from patients, pharmacists and now Washington lawmakers.
This prevented developing countries
from producing
generic versions of patented
drugs, notably treatments for HIV / AIDS and malaria, which they maintained were being sold at unfair
prices.
These include patent expirations, the rise of competition
from generics, a downward pressure on
drug prices, increasing scrutiny
from regulators and health technology assessment bodies, pressure to move research offshore, and the crisis in R&D productivity.
«With the money saved
from using
generic medicines, bulk purchasing, and better approaches to
pricing, we can afford to cover medically necessary
drugs for all Canadians without increasing taxes.»
Doctors, clinic staff and pharmacists, Malani says, can help patients identify options
from drug companies that might reduce costs by reducing copayments or overall
price, and recommend
generic equivalents when available.
We were originally attracted to TEVA because of its leading position in
generic drugs, its free cash flow generation
from its branded
drug division, its recent dividend growth, and its cheap
price to our estimation of its intrinsic value.